Jazz Pharmaceuticals (JAZZ) Retained Earnings (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Retained Earnings of -$651.0 million for Q1 2026, down 162.91% year-over-year from $1.0 billion in Q1 2025, and down 14.49% quarter-over-quarter from -$568.6 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Retained Earnings (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$651.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 162.91% year-over-year to -$651.0 million; the TTM figure through Mar 2026 stood at -$651.0 million (down 162.91% YoY), while the FY2025 annual figure was -$568.6 million, up 40.0% from the prior year.
- Retained Earnings for Q1 2026 stood at -$651.0 million, down from -$568.6 million in the prior quarter.
- The five-year high for Retained Earnings was $1.0 billion in Q1 2025, with the low at -$1.1 billion in Q2 2022.
- The 5-year median for Retained Earnings is -$569.9 million (2025), against an average of -$192.3 million.
- Peak annual rise in Retained Earnings reached 283.23% in 2022, while the deepest fall reached 220.43% in 2022.
- Jazz Pharmaceuticals' Retained Earnings stood at $733.6 million in 2022, then advanced by 19.78% to $878.7 million in 2023, then plunged by 207.85% to -$947.7 million in 2024, then soared by 40.0% to -$568.6 million in 2025, then declined by 14.49% to -$651.0 million in 2026.
- Business Quant data shows JAZZ's Retained Earnings at -$651.0 million in Q1 2026, -$568.6 million in Q4 2025, and -$569.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 1.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Bn |
| Mar 31, 2026 | -651.00 Mn |
| Dec 31, 2025 | -568.60 Mn |
| Sep 30, 2025 | -569.90 Mn |
| Jun 30, 2025 | -485.77 Mn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | -947.67 Mn |
| Sep 30, 2024 | 936.23 Mn |
| Jun 30, 2024 | -888.23 Mn |
| Mar 31, 2024 | 864.04 Mn |
| Dec 31, 2023 | 878.66 Mn |
| Sep 30, 2023 | -1.04 Bn |
| Jun 30, 2023 | -866.82 Mn |
| Mar 31, 2023 | -980.23 Mn |
| Dec 31, 2022 | 733.59 Mn |
| Sep 30, 2022 | 974.31 Mn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -590.72 Mn |
| Dec 31, 2021 | -400.36 Mn |
| Sep 30, 2021 | 865.58 Mn |